company background image
BML

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek WSE:BML Stock Report

Last Price

zł6.18

Market Cap

zł403.3m

7D

-5.8%

1Y

-37.1%

Updated

29 Sep, 2022

Data

Company Financials
BML fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health5/6
Dividends0/6

BML Stock Overview

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., a biotechnology company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland.

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek
Historical stock prices
Current Share Pricezł6.18
52 Week Highzł10.39
52 Week Lowzł2.72
Beta1.65
1 Month Change-21.27%
3 Month Change69.78%
1 Year Change-37.13%
3 Year Change564.52%
5 Year Change432.76%
Change since IPO28.75%

Recent News & Updates

Shareholder Returns

BMLPL BiotechsPL Market
7D-5.8%-4.3%-7.9%
1Y-37.1%-43.4%-35.7%

Return vs Industry: BML exceeded the Polish Biotechs industry which returned -41.7% over the past year.

Return vs Market: BML underperformed the Polish Market which returned -33.1% over the past year.

Price Volatility

Is BML's price volatile compared to industry and market?
BML volatility
BML Average Weekly Movement19.9%
Biotechs Industry Average Movement10.5%
Market Average Movement6.1%
10% most volatile stocks in PL Market11.7%
10% least volatile stocks in PL Market3.8%

Stable Share Price: BML is more volatile than 90% of Polish stocks over the past 3 months, typically moving +/- 20% a week.

Volatility Over Time: BML's weekly volatility has increased from 13% to 20% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1944224Mieczyslaw Starkowiczhttps://biomedlublin.com

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., a biotechnology company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company’s prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50, a product used in treating superficial (non-muscle invasive) bladder tumour; GAMMA anty HBs 200 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; Löwenstein-Jensen medium containing glycerol is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma.

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Fundamentals Summary

How do BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's earnings and revenue compare to its market cap?
BML fundamental statistics
Market Capzł403.31m
Earnings (TTM)zł4.45m
Revenue (TTM)zł43.77m

90.6x

P/E Ratio

9.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BML income statement (TTM)
Revenuezł43.77m
Cost of Revenuezł35.60m
Gross Profitzł8.17m
Other Expenseszł3.72m
Earningszł4.45m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 09, 2022

Earnings per share (EPS)0.068
Gross Margin18.67%
Net Profit Margin10.17%
Debt/Equity Ratio12.3%

How did BML perform over the long term?

See historical performance and comparison